Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109Globe Newswire•30/07/2026•07:30 ET0 ShareWhiz InsightsGenerateGet startedCreate a free account to read the full story.Sign UpAlready have an account? Log inForgot password?
